





Optimized Workflow for On-Line Derivatization for Targeted
Metabolomics Approach by Gas
Chromatography-Mass Spectrometry
Raphaela Fritsche-Guenther 1, Yoann Gloaguen 1,2 , Anna Bauer 1, Tobias Opialla 1 , Stefan Kempa 3,




Gloaguen, Y.; Bauer, A.; Opialla, T.;
Kempa, S.; Fleming, C.A.; Redmond,
H.P.; Kirwan, J.A. Optimized
Workflow for On-Line Derivatization
for Targeted Metabolomics Approach
by Gas Chromatography-Mass





Received: 12 November 2021
Accepted: 14 December 2021
Published: 18 December 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Berlin Institute of Health (BIH) @ Charité—Universitätsmedizin Berlin, BIH Metabolomics Platform,
13125 Berlin, Germany; Raphaela.fritsche@charite.de (R.F.-G.); yoann.gloaguen@mdc-berlin.de (Y.G.);
anabauer@ual.com (A.B.); tobias.opialla@mdc-berlin.de (T.O.)
2 Core Unit Bioinformatics, Berlin Institute of Health (BIH) @ Charité—Universitätsmedizin Berlin,
10117 Berlin, Germany
3 Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin Institute of
Medical Systems Biology, 10115 Berlin, Germany; Stefan.kempa@mdc-berlin.de
4 Department of Academic Surgery, Cork University Hospital, T12 DFK4 Cork, Ireland;
christinafleming49@gmail.com (C.A.F.); henry.redmond@hse.ie (H.P.R.)
* Correspondence: jennifer.kirwan@charite.de
Abstract: Using manual derivatization in gas chromatography-mass spectrometry samples have vary-
ing equilibration times before analysis which increases technical variability and limits the number of
potential samples analyzed. By contrast, automated derivatization methods can derivatize and inject
each sample in an identical manner. We present a fully automated (on-line) derivatization method
used for targeted analysis of different matrices. We describe method optimization and compare results
from using off-line and on-line derivatization protocols, including the robustness and reproducibility
of the methods. Our final parameters for the derivatization process were 20 µL of methoxyamine
(MeOx) in pyridine for 60 min at 30 ◦C followed by 80 µL N-Methyl-N-trimethylsilyltrifluoracetamide
(MSTFA) for 30 min at 30 ◦C combined with 4 h of equilibration time. The repeatability test in plasma
and liver revealed a median relative standard deviation (RSD) of 16% and 10%, respectively. Serum
samples showed a consistent intra-batch median RSD of 20% with an inter-batch variability of 27%
across three batches. The direct comparison of on-line versus off-line demonstrated that on-line was
fit for purpose and improves repeatability with a measured median RSD of 11% compared to 17%
using the same method off-line. In summary, we recommend that optimized on-line methods may
improve results for metabolomics and should be used where available.
Keywords: automated derivatization; on-line derivatization; optimization; gas-chromatography
mass spectrometry; validation; metabolomics; quality assurance (QA); quality control (QC)
1. Introduction
Gas chromatography-mass spectrometry (GC-MS) has been widely used for the analy-
sis of highly polar compounds such as amino acids, sugars, sugar alcohols and phospho-
rylated compounds. Derivatization of the sample is normally necessary to convert the
metabolites into their volatile counterparts to facilitate analysis by GC-MS. Derivatization
reduces polarity, increases thermal stability and improves peak shape, resolution and
intensity [1]. Many derivatization methods are available while methoximation (MeOx)
followed by silylation is one of the most widely used methods [2]. The MeOx reaction
converts free carbonyl functional moieties (C=O) into oxime derivatives (CH2ON) and
prevents formation of cyclic structures especially from carbohydrates and steroids. This
reduces the number of possible stereoisomers per compound and increases sensitivity of
detection. Pyridine is used as both a solvent and as a catalyst in this reaction. Silylation is
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then typically performed to make compounds more volatile. The most common silylation
reagent is MSTFA (N-Methyl-N-trimethylsilyltrifluoracetamide) which substitutes active
hydrogens on the metabolite with a trimethyl-silyl group [-Si(CH3)3-]. A further advantage
of silylation is the ease-of-use and that the derivatization reaction can be performed at
low temperatures.
Most of the protocols to measure polar metabolites are designed for manual (hereafter
off-line) derivatization. Major challenges with off-line derivatization are that it is time
consuming, and most derivatization products are somewhat unstable. Since most off-
line derivatization is performed batch wise, it also leads to variable equilibration times
since the samples are waiting different lengths of time in the autosampler before analysis.
Thus, derivatization of more than a small batch of samples at once can result in a high
variability among the samples [2]. Multiple peaks are usually produced when silylation
is incomplete. Factors like temperature, time of derivatization and the volume of the
derivatization agent contribute to the reaction speed and completeness of derivatization.
Derivatization conditions therefore directly impact on the repeatability and reproducibility
of sample analyzes.
An automated (hereafter on-line) derivatization method can be beneficial. It allows
a consistent derivatization time of samples prior to analysis, potentially giving more
robust and reproducible data [3]. The on-line workflow also allows the largely unattended
analyzes of large sample series. The results are independent of operator and location and
should result in highly reproducible data sets.
Zarate et al. (2016) [1] have previously presented an automated derivatization protocol
by GC-MS using the commercially available software Maestro from Gerstel GmbH. The
performance of on-line and off-line derivatization was tested in wine and plasma. However,
no parameter optimization regarding chemical volumes, incubation time and temperature
or equilibration time was performed. Abbiss et al. (2015) [2] have also investigated auto-
mated derivatization of both silylating agent and batch versus just-in-time derivatization
but did not optimize setting parameters [4]. The aim of the current study was to develop a
fully automated derivatization method which could then be applied for targeted analysis
of common human and animal matrices. We describe the method optimization steps and
compare the data obtained from both off-line and on-line derivatization methods. The
developed automated derivatization method should perform at least as well as the off-line
derivatization in its detection and reproducibility capability.
2. Results
All the samples from off-line and on-line derivatization were run in scan mode to
obtain both targeted and untargeted metabolic profiles. However, in the current study
we selected 42 specific metabolites from the central carbon metabolism (CCM) to cover
the biological classes glycolysis, amino acids and metabolites from the tricarboxylic cycle
(TCA) as well as some chemical classes herein named as other (nucleobases/nucleosides,
phosphate compounds, short chain fatty acids, sugar alcohols, carboxylic acids and glycerol
metabolites) that we have previously targeted in other studies (Supplementary Material
Table S1) [5–7]. The detection of these compounds after preparation with off-line and
on-line derivatization protocols were directly compared.
In metabolomics, data reproducibility is usually reported as relative standard devi-
ation (RSD in %) of a repeated sample measurement, e.g., a quality control (QC) sample
analyzed multiple times over several batches. A commonly accepted maximum tolerance
for GC-MS in metabolomics studies is 30% [8,9]. An RSD of less than 15% is considered as
very good reproducibility [10].
For our optimization studies, a calibration mixture was used containing the metabo-
lites of interest in designated low (1:100 diluted), middle (1:10 diluted) and high concen-
tration (1:1 not diluted) solutions (Supplementary Material Table S2). For the parameter
optimization we focused on the 1:10 calibration mixture. When using plasma or serum as
matrix, most of the detected metabolites were detected in the low concentration range of
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our calibration mixture (low signal intensity) (Supplementary Material Figures S1 and S2),
whereas for liver, the compounds were more in a medium range (Figure 1). Only glucose
was detected at high intensities in mouse liver samples.
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Figure 1. Concentration range of 30/42 detected compounds in mouse liver. A calibration mixture at
high (1:1), middle (1:10) and low (1:100) concentration was used for comparison (one for calibration
mixture and n = 18 for liver). A minimum/maximum normalization was performed on the calibration
mixture for the single compounds.
2.1. Optimization of the Derivatization Parameters
We started with our current off-line protocol (Supplementary Material Table S3). A
few modifications were immediately required to enable it to work as an on-line method
due to technical limitations of the multipurpose sampler (MPS). This included changing the
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incubation temperature for both the MeOx/pyridine and MSTFA incubation derivatization
step from 30 ◦C to 37 ◦C. Changing the temperature of the agitator between the two steps
is difficult and time consuming during a sequence, so both reactions were conducted under
the same temperature conditions. An equilibration time of 4 h was set for the on-line
method, while it continued to be variable for samples prepared batch-wise in the off-line.
In addition, we optimized some other parameters to improve the derivatization results
(Supplementary Material Table S3, see on-line optimized). This includes the preparation of
MeOx/pyridine and MSTFA aliquots at the beginning of the sequence for all samples, the
removal of the quick mix shaking step after addition of MeOx/pyridine or MSTFA and the
reduction of the agitator speed from 750 rpm to 250 rpm. Syringe parameters were changed
to reduce the number of misinjections and to avoid air bubbles during aspiration of the
liquids (Supplementary Material Figure S3). The workflow of the parameter optimization
for MeOx/pyridine volume, incubation time and temperature and the equilibration time
of the sample is shown in Figure 2.Metabolites 2021, 11, x FOR PEER REVIEW 5 of 16  
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2.1.1. MeOx Volume
First, we tested three different MeOx volumes (20 µL, 40 µL, 60 µL all at 40 mg
MeOx per mL pyridine concentration). An alkane mixture for reliable retention index
calculation was included. Alkane 32 was used to analyze the instrumental drift throughout
the run. Cinnamic acid was used as an internal standard for compound normalization. An
overall reduction of around 30% in the average peak area was observed for alkane 32 and
cinnamic acid as the volume of MeOx increased (mean area alkane 32 for 20 µL = 3.0 × 105,
40 µL = 2.4 × 105, 60 µL = 2.1 × 105; mean area cinnamic acid for 20 µL= 6.5 × 104,
40 µL = 5.3 × 104, 60 µL = 4.6 × 104). This was likely a dilution effect due to increasing total
volume. A measure of 20 µL MeOx provided the overall best results for the 1:10 calibration
mix (Table 1). The median RSD was 17% for 20 µL MeOx volume compared to 27% and
33% for 40 µL and 60 µL (p = 8.53 × 10−7 by Kruskal-Wallis (KW) test), respectively. In
line, the median RSD per biological class was lower when using 20 µL MeOx compared
to 40 µL and 60 µL. It was found that RSDs were significantly worse when 60 µL was
used compared to both 20 µL and 40 µL (p = 1.23 × 10−6 by KW test). The numbers of
compounds detected were 33 using 20 µL, 33 using 40 µL and 32 when using 60 µL MeOx.
Adenine and glucose-6-phosphate were only detected in the 20 µL MeOx condition, while
fructose-6-phosphate was only detected using 40 µL MeOx. Cytosine could be detected
in the 40 µL and 60 µL MeOx condition but not for 20 µL. The measurement response,
as measured by the normalized peak area for each compound, was, on average, greater
per compound when using 20 µL of MeOx compared to 40 µL or 60 µL (Supplementary
Material Figure S4). For the 1:1 calibration mix dilution, a lower median RSD was found
for 60 µL MeOx (21% for 20 µL, 17% for 40 µL, 15% for 60 µL), albeit with the loss of up
to two compounds in the 60 µL condition (36 compounds) compared to both 20 µL MeOx
(37 compounds, adenine could be detected) and 40 µL MeOx (38 compounds, adenine and
adenosine could be detected) (Supplementary Material Table S4). For the 1:100 calibration
mix dilution, the overall best conditions were observed using 60 µL of MeOx. However,
two compounds more (phenylalanine, 4-amino butanoic acid) could be detected in the
20 µL and 40 µL conditions (24, 24, 22 for 20 µL, 40 µL, 60 µL, respectively). The median
RSD was much higher in 20 µL and 40 µL compared to 60 µL (32%, 34% and 20% for
20 µL, 40 µL and 60 µL, respectively) which may be due to signal interference from other
substances in the same mixture (so-called “matrix effects”).
Table 1. Combined results for the optimization of the on-line parameters for derivatization. The 1:10
calibration mix dilution was used.












































In a second step, the different incubation times for both MeOx/pyridine and MSTFA
were tested. Our first observation was that results were highly dependent on individual
metabolites (although there were trends within a class) and on the overall metabolite
concentrations. Our original off-line method used an incubation time of 90 min for MeOx,
then 60 min for MSTFA (90/60 min), but for the on-line method we found the best condition
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for the 1:10 calibration mix dilution was 60/30 min (Table 1). Repeatability, as measured
by RSD, is better overall (median RSD 15%), and better for virtually all of the individual
biological classes when a 60/30 min incubation protocol is used (Supplementary Material
Table S5). This combination also resulted in the highest number of detected compounds
(34). Tyrosine, methionine and fructose-6-phosphate could be detected only when using
these conditions, although lysine and ribose-5-phosphate were only detected using the
30/30 min protocol and citric acid was only detected using the 90/60 min protocol. Violin
plots of the ratio of normalized peak areas of the detected compounds visualize how areas
(and therefore sensitivity) changes overall between two different methods. The ratios of
normalized peak areas were similarly distributed when using the indicated incubation
times, however, with slight exceptions (Supplementary Material Figure S4). Concentration
affected both reproducibility, detection and the optimal derivatization times. For the
1:1 calibration mix, the repeatability was marginally better when 90/60 min was used
(12% compared to 13% and 18% for 30/30 min and 60/30 min, respectively), while the
number of detected compounds was marginally higher when the 30/30 min protocol
was used (37, 34, 36 for 30/30 min, 60/30 min and 90/60 min, respectively). Overall,
and perhaps unsurprisingly, this more concentrated mixture performed best for both
repeatability and detection. For the 1:100 calibration mix dilution, compound RSDs were
shown with a 16% decrease in the median RSD for the 90/60 min incubation condition,
alongside a corresponding 20% decrease in the number of detected compounds (24, 25 and
19 compounds detected for 30/30 min, 60/30 min and 90/60 min, respectively).
2.1.3. Incubation Temperature
As a third optimization parameter, we analyzed different incubation temperatures for
both MeOx/pyridine and MSTFA. For the on-line method it is not possible to change the
temperatures in the agitator within a few minutes. Therefore, one optimal temperature
for both derivatization steps were analyzed. Once again, we saw an effect of metabolite
concentration on the results. The optimized temperature for the 1:10 calibration mix
dilution was 30 ◦C (Table 1). The median RSD was 10% (10% 37 ◦C, 21% 45 ◦C; 30 ◦C
versus 45 ◦C p = 1.37 × 10−2 and 37 ◦C versus 45 ◦C p = 7.88 × 10−6) and 38 compounds
could be detected (37 at 37 ◦C, 36 at 45 ◦C). Notably, derivatization of amino acids and
glycolytic phosphates as well as the two carboxylic acids lactic acid and pyruvic acid
performed significantly better when 37 ◦C was used. The analysis of the peak area revealed
a high spread in the 30 ◦C compared to 37 ◦C with half of the compounds showing a
decrease and half an increase in the peak area (Supplementary Material Figure S4). For
1:1 calibration mix dilution the lowest median RSD (27% 30 ◦C, 16 % 37 ◦C, 16 % 45 ◦C)
and 3 extra compounds were found using 37 ◦C (Supplementary Material Table S6). The
number of detected compounds were broadly similar for 1:1 and 1:10 calibration mixes
(range 36–39), while a notable decrease was seen in the 1:100 quant across all incubation
temperatures (range 29–32) reflecting the substantially lower concentration. This is also the
likely explanation for the observed higher median RSDs seen in this group.
2.1.4. Equilibration Time
Four different equilibration times were tested (0 h, 2 h, 4 h and 8 h). The lowest
median RSD was found for 0 h (11%), while 4 h and 8 h both had median RSDs of 15%
(Table 1). The highest median RSD was found when using 2 h of equilibration time (21%).
This is also reflected in the median RSDs per biological group. Significant differences
were found comparing 0 h to 2 h (p = 3.10 × 10−5), 2 h to 4 h (p = 4.49 × 10−3) and 2 h
to 8 h (p = 3.43 × 10−2). The number of compounds detected was equal for 2 h and 4 h
(36) and 0 h and 8 h (34). The 0 h of equilibration time showed slightly lower peak areas
compared to 4 h, while for 2 h the areas were equivalent to 4 h. The measurement from
the 8 h equilibration time showed a wider spread but with a trend of lower peak areas
compared to 4 h (Supplementary Material Figure S4). For the 1:1 calibration mix dilution, 2
and 8 h showed the lowest median RSD (both 11%; 21% 0 h and 28% 4 h) (Supplementary
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Material Table S7). A measure of 38 compounds were detected with an equilibration time
of 4 h and 36 for the other tested conditions. For the 1:100 calibration mix dilution the
best condition is 8 h of equilibration time giving a median RSD of 16% and 27 detected
compounds (median RSD 29%, 21%, 35% and 25, 24 and 27 compounds for 0 h, 2 h and 4 h,
respectively). To reduce the total run time, we compromised on using 4 h for equilibration
of the samples after the derivatization process. This enables detection of two additional
compounds but sacrifices some technical reproducibility. This may need to be changed if
matrices with predominantly low or high compound concentrations are used.
To see which tested condition had the major effects the absolute RSD change and
the percent of increase per tested condition were analyzed. Our optimization method
suggested that the determination of the MeOx volume makes the largest overall difference
to reproducibility (a 16% absolute difference in RSD and a 95% increase in area) although
the incubation temperature had a 12% absolute difference in median RSD between the
highest (22%) and lowest (10%) median RSD values measured.
In summary, our final defined parameters for the 1:10 calibration mix dilution was
20 µL of MeOx/pyridine for 60 min at 30 ◦C followed by 80 µL MSTFA for 30 min at 30 ◦C
combined with 4 h of equilibration time.
2.2. Repeatability and Reproducibility
Like any analytical field, metabolomics requires methods that are robust and repro-
ducible. To test the repeatability of this method, 45 replicates of human plasma and
18 replicates of mouse liver were analyzed using the final parameters (Table 2, Supple-
mentary Material Tables S8 and S9). To test the reproducibility of the method, 9 quality
control samples (serum samples pooled after extraction from healthy and sick patients)
were analyzed over 3 batches within the scope of a biological study, i.e., realistic conditions
(Table 2 and Supplementary Material Table S10). Number of metabolites detected, num-
ber of missing values and median RSD were used as indicators of sensitivity, method
robustness (including derivatization completeness) and reproducibility.
Table 2. Repeatability and reproducibility test. Results are from plasma and liver (single batch) and
pooled serum quality control (QC) samples (analyzed over three large batches of around 115 samples
per batch). RSD: relative standard deviation.
Parameter Plasma Liver Batch 1 Batch 2 Batch 3
Number of metabolites 22.8 ± 0.5 37 ± 0 20.3 ± 1.9 20.2 ± 2.4 20.2 ± 2.2
Number of missing values 11 (0.8%) 0 (0%) 24 (11%) 25 (12%) 25 (12%)
Median RSD 16% 10% 21% 20% 19%
RSD range 11–28% 2–56% 3–42% 12–69% 13–39%
The repeatability test in plasma showed a median RSD of 16% ranging from 11%
(valine) to 28% (alanine) for individual compounds for 44/45 samples. One sample was
lost due to a misinjection. Ten metabolites showed a median RSD of less than 15% indicating
a very good repeatability. For the individual biological classes, a median RSD of 18% was
found for amino acids, 13% for glycolysis and 15% for TCA cycle. The analysis of the MeOx
and trimethylsilyl (TMS) groups revealed an RSD of 15% for metabolites with 4 TMS groups
(3 metabolites, all RSD 15%), 20% for metabolites with 3 TMS groups (8 metabolites, RSD
range 13–52%), 25% for metabolites with 2 TMS groups (12 metabolites, RSD range 12–50%)
and 37% for metabolites with 1 TMS group (4 metabolites, RSD range 19–37%). MeOx
products showed a median RSD of 16% (2 metabolites, RSD 12% and 20%). On average
23 compounds were found in the 44 plasma samples. Of the data, 1% were missing values.
The repeatability test in liver showed a median RSD of 10% ranging from 2% (malic
acid and succinic acid) to 56% (4-amino butanoic acid) for individual compounds. A total
of 22 metabolites showed a median RSD of < 15% indicating a very good repeatability. For
the individual biological classes, a median RSD of 13% was found for amino acids, 21% for
glycolysis and 3% for TCA cycle. The analysis of the MeOx and TMS groups revealed an
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RSD of 7% for metabolites with 4 TMS groups (6 metabolites), 21% for metabolites with
3 TMS groups (16 metabolites), 22% for metabolites with 2 TMS groups (17 metabolites)
and 13% for metabolites with 1 TMS group (3 metabolites). MeOx products showed a
median RSD of 22% over 7 metabolites). On average, 37 compounds were found in the
18 liver samples. No missing values were present.
For the reproducibility study, pooled serum samples were used. The overall sequence
length was spread over three batches and comprised 115, 115 and 118 injections in total
for batch 1, 2 and 3, respectively, including washes (n = 26, n = 25, n = 29), equilibration
samples (n = 2 per batch), identification mixtures (n = 4), quantification mixtures (n = 8),
long term internal reference QC liver samples (n = 3), pooled QC samples (n = 10) and
human serum samples (n = 59, n = 60, n = 62). The biological results from this study
are detailed in another paper. Two QCs were measured at the beginning and the end of
each batch. The rest of the QCs were equally distributed over the whole sequence. The
reproducibility test of the pooled serum samples showed a consistent intra-batch median
RSD of around 20% ± 1% while the inter-batch variability across three batches was 27%.
For individual metabolites, the measured variability was considerably higher: intra-batch
range 3% to 69%, inter-batch range 15% to 77%. Equivalent numbers of compounds could
be detected in all three batches.
2.3. Comparison of on-Line to off-Line Derivatization
To benchmark the results, we compared on-line to off-line derivatization (Table 3). For
the off-line experiments, both the original and the newly adapted for on-line derivatization
protocols (including new time and temperature parameters) were used. Human plasma
samples were aliquoted, extracted, derivatized and analyzed for each condition (each n = 9).
The mean number of detected compounds were similar across all three protocols (23.4,
24.2 and 24.4 for on-line, off-line (original) and off-line with on-line parameters (OLOLP),
respectively); however, the number of missing values was slightly but not significantly
higher when using the on-line protocol (6% compared to 3% for off-line and OLOLP).
A typical chromatogram of a plasma sample prepared with on-line method is shown in
Supplementary Material Figure S5. For the compounds common to all methods, the lowest
median RSD was found in the on-line derivatization (11%) compared to off-line (21%,
p = 4.51 × 10−4) and OLOLP (17%, p = 4.23 × 10−2). The lowest individual compound
RSD (2% for phenylalanine) was found for the OLOLP protocol (compared to 4% for both
pyruvic acid and phenylalanine for on-line and off-line, respectively). By contrast, proline
had the highest individual compound RSD (38%) in the on-line method. The highest
individual RSD for off-line protocols was found for ribose (48%) and adenine (50%) for
OLOLP. The distribution of the individual RSDs is shown in Figure 3. This demonstrates
that there are compound-specific differences in performance of protocols. When analyzing
the different methoximation and silylation products, lower median RSDs were found in
the on-line protocol for 1 TMS (20%, 21%, 22%), 2 TMS (16%, 23%, 21%), 3 TMS (9%, 22%,
16%), 4 TMS (7%, 13%, 11%) and MeOx groups (20%, 29%, 45%) compared to original
and OLOLP, respectively. Four of our measured metabolites were detected with two
different TMS groups (leucine, phenylalanine, threonine and valine). The ratio between
the two TMS groups detected was higher using the on-line compared to both off-line
conditions (Supplementary Material Table S11). When all metabolites were accounted for,
a significantly higher normalized peak area was found for on-line compared to off-line
(p = 1.50 × 10−2) and on-line compared to OLOLP (p = 2.53 × 10−2) conditions.
In summary, the optimized parameters indicate that the on-line derivatization method
was fit for purpose and may have some advantages over off-line methods in repeatability
and reproducibility.
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Table 3. Comparison of on-line and off-line settings. RSD: relative standard deviation.
Parameter On-Line Off-Line (Original) Off-Line with On-Line Settings (OLOLP)
Replicates 9 9 8
Number metabolites 23.4 ± 0.73 24.2 ± 0.83 24.4 ± 0.71
Number of missing values 14 (6%) 7 (3%) 5 (3%)
Median RSD 11% 21% 17%
RSD range 4–38% 4–48% 2–50%
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We optimized our derivatization protocol using MeOx/pyridine and MSTFA as deri-
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3. Discussion
The aim of the current study was to develop a fully automated derivatization method
for targeted metabolic profiling of different matrices which allows consistent derivatization
time of samples prior to inject on thus givi g ore robust and reproducible data. More
traditional of -line d rivatiza ion necessitate var able within-batch equilibration times
after d rivat zation, which affects he reproducibility and qua ity of the acquir d data [3].
Equilibr tion time refers t the time following th derivat zation steps where the sample is
left to stabilize at room tempe atu e before nj ction. Equivalent equilibration times for all
samples is the major dvantage f on-line derivatization and should lead to more consistent
results and potentially better sensitivity, compared to off-lin derivatizatio . Equilibration
ti es all w more complete erivatization of compounds with slower reactio times but
may also result in the degradation of some less stable derivatized co pounds. Optimal
equilibration times are therefore compound dependent. An on-line method allows better
control of both the derivatization process and time before injection of the samples thus
reducing technical variation between the samples.
We optimized our derivatization protocol using MeOx/pyridine and MSTFA as deriva-
tizing agents. Since the derivatization time was longer than the GC-MS analysis time, the
use of a commercial software (Maestro software available for Gerstel) further enabled us to
minimize total instrument time by allowing us to overlap the derviatization sequences of
individual samples and still consistently inject samples at the same stage of derivatization.
Methoximation is performed to inhibit ring formation of reducing sugars by protection of
the aldehyde and ketone groups [11]. It stabilizes ring sugars in an “open” linear formation
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and results in two stereoisomers (cis and trans), which will later be separated by GC-MS. A
l derivatization time ensures the completion of methoxymation; however, this could also
result in progressive degradation of heat labile metabolites [12]. In addition, we observed
that the overall areas decrease by around 30% with increasing volumes of MeOx. We
attribute this to a dilution effect due to the increased volume of solvent in the final sample.
Our optimization method suggested that the determination of the MeOx volume and
incubation temperature makes the largest overall difference to reproducibility. With our
optimized derivatization protocol, we anticipate the method could be used for the analysis
of a wide range of biological samples with different matrices.
Our presented optimized on-line method showed a good repeatability for different
compound classes including amino acids, sugars and organic acids. An inter-batch study
was conducted comparing pooled quality control samples over three batches. The repro-
ducibility over a long sequence (more than 100 injections at once) was in an acceptable
range (27%). This is particularly impressive when considering that the matrix itself (human
serum) can be challenging to analyze due to a large dynamic range and many very low
intensity peaks of interest. Plasma and serum have proven to be particularly challenging
matrices to analyze, with the analysis dominated with large MSTFA and contaminant
peaks, while peaks of interest are often at low intensities. In some cases, compounds
were detectable, but had poor peak shape. Poor peak shape makes quantifying peak area
potentially unreliable, and these peaks are best excluded for further statistical analysis.
Since poor peak shapes tend to be reflected in poorer RSDs, these peaks are subsequently
excluded as part of the normal quality control RSD filtering which we routinely use in our
lab for biological datasets. However, it is still judicious to validate important biological
findings by re-examining raw data.
A further advantage of on-line derivatization is that a greater number of samples can
be analyzed in one batch. Minor disadvantages of on-line derivatization are the higher
costs (larger volume of chemicals, glass vials and magnetic lids are required), more training
required for sequence programming and the potential loss of some specific metabolites.
However, these disadvantages are relatively small compared to the overall advantages
offered by the convenience and reproducibility of the method.
We were surprised that the concentration of a particular mixture should affect the
optimal derivatization parameters. While for some factors, this may be availability of
derivatizing agent or dilution, other factors such as temperature are less easily explainable,
although there may also be a concentration dependent general evaporation or vaporization
effect of specific metabolites that occurs at higher temperatures or over longer times.
We had also anticipated a greater range of results between the metabolic classes,
especially where there were different numbers of maximum TMS groups. We did indeed
see some differences in optimal derivatization conditions between the classes, and we also
saw that the median RSDs were variable between the TMS groups. However, the number
of TMS groups did not seem to affect the measured optimal parameters overall, probably
because there were only four compounds where there was consistently more than one
TMS state.
Our developed and optimized on-line derivatization method allows the immediate
derivatization of samples prior to injection giving more robust and reproducible data [3].
Additionally, the method saves personnel time with both sample preparation and later
data processing. Further development of the instrument method may improve results for
particular matrices, e.g., serum.
4. Materials and Methods
All chemicals used were analytical grade.
4.1. Extraction of Calibration Standards
A mix of commercially available, biologically relevant calibration standards (calibra-
tion mix dilution) were used in our method development tests [13]. The mix was diluted
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to make high (1:1, undiluted), middle (1:10) and low (1:100) metabolite concentration
mixes. A biphasic extraction of the standards was performed as follows: 1 mL of methanol
(MeOH, Chemsolute/Th.Geyer, Berlin, Germany, cat-number 1428.1000 LC-MS grade),
chloroform (CHCl3, Sigma-Aldrich, St. Louis, MO, USA, cat-number 132950 >99.8% grade)
and water (H2O, VWR, Radnor, Pennsylvania, US, cat-number 83645.290) in a 5:2:1 ratio
plus 2 µg/mL cinnamic acid (Sigma-Aldrich, St. Louis, MO, USA, cat-number C80857) was
added to the calibration standards and shaken for 15 min at 4 ◦C. A measure of 0.5 mL
of H2O was added to introduce phase separation followed by shaking for 15 min at 4 ◦C
and centrifugation at 4.149× g for 10 min at 4 ◦C. Next, 500 µL aliquots of the polar phase
was collected in GC-MS champagne vials and dried over night at 30 ◦C with 1.550× g
at 0.1 mbar vacuum using a rotational vacuum concentrator (RVC 2-33 CDplus, Christ,
Osterode am Harz, Germany). The dried aliquots were stored at −80 ◦C until use when
they were prepared as described below.
4.2. Plasma and Serum Extraction
Human plasma was drawn from healthy volunteers in accordance with the ethical
standards of the institutional review board of the Charité-Universitätsmedizin Berlin (ethi-
cal approval EA2/046/17). Human serum was obtained from healthy patients and patients
with colorectal cancer. Ethical approval was prospectively approved by CREC (Clinical Re-
search Ethics Committee of the Cork Teaching Hospitals), Cork, Ireland [reference number:
ECM5(12)-11/09/07& ECM3-05/06/18]. Frozen plasma or serum was thawed, vortexed
and 25 µL of the plasma or serum was added into prechilled and aliquoted MeOH (112.5 µL)
followed by 15 s of vortexing. Afterwards, a MeOH/CHCl3 mixture (987.5 µL) including
6 µg/mL cinnamic acid and 382.5 µL H2O was added, vortexed for 15 s and left on ice for
10 min to separate the biphasic mixture. Samples were centrifuged at 2.560× g for 20 min at
4 ◦C and then left at room temperature for 10 min to equilibrate. Next, 300 µL of the polar
phase were collected in GC-MS champagne vials and dried over night at 30 ◦C at 1.550× g
at 0.1 mbar vacuum using a rotational vacuum concentrator (RVC 2-33 CDplus, Christ,
Osterode am Harz, Germany). Pooled quality control samples from all analyzed serum
samples were generated after extraction and used in this study to analyze reproducibility.
4.3. Liver Extraction
Mouse liver (obtained from already sacrificed mice at animal facility at Max Del-
brück Center, Berlin, Germany) was weighed and homogenized using the Precellys 24 tis-
sue lyzer (Bertin Instruments, Montigny-le-Bretonneux, France). A measure of 1 mL of
MeOH:CHCl3:H2O in a ratio of 5:2:1 including 2 µg/mL cinnamic acid was added to 50 mg
of tissue and incubated for 15 min at 4 ◦C with continuous shaking. Afterwards, 0.5 mL
of H2O was added and incubated for 15 min at 4 ◦C with continuous shaking following
centrifugation at 4.149× g for 5 min at 4 ◦C. Next, 500 µL aliquots of the polar phase
were collected in GC-MS champagne vials and dried over night at 30 ◦C with 1.550× g
at 0.1 mbar vacuum using a rotational vacuum concentrator (RVC 2-33 CDplus, Christ,
Osterode am Harz, Germany). The dried aliquots were stored at −80 ◦C until use when
they were prepared as described below.
4.4. GC-MS Metabolomics Measurement of Key Central Carbon Pathway Metabolites
Extracts were removed from the freezer and dried in a rotational vacuum concentrator
(RVC 2-33 CDplus, Christ, Osterode am Harz, Germany) for 60 min before further process-
ing to ensure there was no residual water which may influence derivatization efficiency.
4.4.1. On-line Derivatization
A Gerstel autosampler (Multi Purpose Sampler; Mülheim, Germany) and the commer-
cially available software Maestro (version 1.4.40.0) was used for automatically overlapping
derivatization and GC-MS acquisition. Derivatization parameters tested included (1) MeOx
(cat-number 226904) in pyridine (cat-number 270970) volume (both Sigma-Aldrich, St.
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Louis, MI, USA), (2) incubation time for MeOx in pyridine and MSTFA (Macherey-Nagel;
Düren, Geramany, cat-number 701270.201), (3) incubation temperature for MeOx in pyri-
dine and MSTFA and (4) equilibration time of the sample.
A sequence was generated to set up an automated methoxymation and trimethylsilyl
derivatization run (Figure 4). Champagne vials (Zinsser Analytic, Eschborn, Germany)
with magnetic lids (Fisher Scientific, Hampton, VA, USA) were used. Dried extracts were
dissolved in 20 µL (40 µL or 60 µL for optimization studies) of MeOx solution (40 mg/mL in
pyridine) and incubated for indicated time, temperature and agitator shaking, followed by
the addition of 80 µL of MSTFA containing an alkane mix (20 µL per 1 mL of MSTFA, C10
(cat-number 457116), C12 (cat-number 297879), C15 (cat-number P3406), C17 (cat-number
51578), C19 (cat-number 747158), C22 (cat-number 134457, C28 (cat-number O504), C32 (cat-
number 44253) and C36 (cat-number H12572) in 50% MeOH, all Sigma-Aldrich, St. Louis,
MO, USA) and incubated for indicated time, temperature and agitator shaking. After
finishing the derivatization, the vial remained on tray for indicated times (equilibration)
before contents were injected for analysis.
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4.4.2. Off-line Derivatization
Two off-line derivatization methods were used to compare to the on-line derivatization
method. One used the same protocol as used for the on-line derivatization, except it
was done batch-wise by hand (and so equilibration times varied across the batch). The
other followed our original protocol and was also performed batch-wise [5]. For off-line
derivatization dried extra ts were dissolved in 20 µL of MeOx solution (40 mg/mL in
pyridine) and incubated for 90 min and 30 ◦C in a thermoshaker (800 rpm), followed by
the addition of 80 µL of MSTFA (which contained the same alkane mix as for on-line) and
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incubated for 60 min at 30 ◦C in a thermoshaker (800 rpm). For the off-line with on-line
parameters (OLOLP), dried extracts were dissolved in 20 µL of MeOx solution (40 mg/mL
in pyridine) and incubated for 60 min at 30 ◦C in a thermoshaker (300 rpm), followed by
the addition of 80 µL of MSTFA plus alkane mix and incubation for 30 min at 30 ◦C in a
thermoshaker (300 rpm). After centrifugation for 10 min at maximum speed, 30 µL was
transferred to GC-MS champagne vials and closed with appropriate lids (Labconco, Kansas
City, MO, USA).
4.4.3. Instrumentation
An identification mixture for reliable compound identification was prepared and
derivatized in the same way, and an alkane mixture for reliable retention index calculation
was included [14]. Metabolite analysis was performed on a Pegasus HT GC-TOFMS System
(LECO Corporation, St. Joseph, MN, USA) complemented with an auto-sampler (Gerstel
MPS DualHead with CAS4 injector, Mühlheim an der Ruhr, Germany). The samples
were injected in split mode (split 1:5, injection volume 1 µL) in a temperature-controlled
injector with a baffled glass liner (Gerstel, Mühlheim an der Ruhr, Germany). The following
temperature program was applied during sample injection: for 2 min the column was
allowed to equilibrate at 68 ◦C, then the temperature was increased by 5 ◦C/min until
120 ◦C, then by 7 ◦C/min up to 200 ◦C, then by 12 ◦C/min up to a maximum temperature
of 320 ◦C which was then held for 7.5 min. Gas chromatographic separation was performed
on an Agilent 7890 (Agilent Technologies, Santa Clara, CA, USA), equipped with a VF-5
ms column (Agilent Technologies, Santa Clara, CA, USA) of 30 m length, 250 µm inner
diameter, and 0.25 µm film thickness. Helium was used as the carrier gas with a flow rate
of 1.2 mL/min [13]. The spectra were recorded in a mass range of 60 to 600 m/z with
10 spectra/sec. The GC-MS chromatograms were processed with ChromaTOF software
(LECO Corporation, St. Joseph, MN, USA) including baseline assessment, peak picking
and computation of the area. A minimum signal to noise ratio of 10 was used to pick
peaks. Data were initially automatically annotated and integrated using ChromaTOF
software Version 4.72.0.0, but then manually checked and adjusted to assume correct peak
annotations and integrations.
4.4.4. Data Analysis
The data were exported and merged by an in-house written R-script. A total of 42
targeted metabolites from the central carbon metabolism covering glycolysis, tricarboxylic
cycle, amino acids, nucleobases/nucleosides, pentose phosphate pathway, short chain
fatty acids, sugar alcohols, carboxylic acids and glycerol pathway were selected for the
reference search (Supplementary Material Table S1) [13]. Microsoft Excel (Microsoft Excel
2013 15.0.5327.1000) and R Studio (version 1.3.1056) were used for data analysis and Adobe
Illustrator (version 16.0.0) was used for visualization. For the calibration mix, dilutions 1:1,
1:10 and 1:100 were each measured in a total of 5 replicates. The metabolites were consid-
ered valid when they appeared in minimum of n = 3 replicates per condition. The peak
area of each metabolite was calculated by normalization to the internal standard cinnamic
acid. The measured derivatives were summarized. Evaluation of optimal parameters was
achieved by the number of compounds, missing values, individual, median RSDs and
median RSDs per biological class. For reproducibility studies using pooled serum samples
the overall sequence length was 115, 115, 118 injections containing washes (n = 26, n = 25,
n = 29), equilibration samples (n = 2), identification mixtures (n = 4), quantification mixtures
(n = 8), liver QC samples (n = 3), pooled QC samples (n = 10) and human serum samples
(n = 59, n = 60, n = 62), for batch 1, 2 and 3, respectively. Two QCs were measured at the
beginning and the end of each batch. The rest of the QCs was equally distributed over the
whole sequence. Number of metabolites detected, number of missing values and median
RSD were used as indicators of sensitivity, method robustness (including derivatization
completeness) and reproducibility, respectively. A Kruskall-Wallis test followed by a Tukey
Kramer multiple comparison test was conducted to assess the significance of differences
Metabolites 2021, 11, 888 14 of 15
between conditions on rankings of RSD per compound and the detected normalized area
per compound. The RSDs were ranked in decreasing order (a low RSD signals good re-
peatability), while areas were ranked in increasing order (higher intensity equals greater
sensitivity). Missing values were ignored. Statistical significance was set at 95 % (p ≤ 0.05).
The Pearsons Chi/squared test was used to test statistical significance (p ≤ 0.05) of missing
values in the on-line and off-line conditions.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/metabo11120888/s1, Supplementary Table S1. List of metabolite derivatives and their
biological group used for reference search. MeOX: Methoxyamine hydrochloride. PPP: Pentose
phosphate pathway. SCFA: short chain fatty acid. TCA: Tricarboxylic acid cycle. TMS: Trimethylsilyl
derivatives. Supplementary Table S2. Composition of the calibration mix dilution for high (1:1),
middle (1:10) and low (1:100) concentration (nM) used for each metabolite. Supplementary Table S3.
Off-line and on-line parameters for optimization of the method. Supplementary Table S4. MeOx
volume tested for optimization of derivatization conditions. Table of relative standard deviations
(RSD) per compound and the median RSD overall and per biological classes in % for the scaled peak
areas per metabolite. CMD: calibration mix dilution. Number of replicates vary due to occasional
misinjections. Supplementary Table S5. Incubation time tested for optimization of derivatization
conditions. Table of relative standard deviations (RSD) per compound and the median RSD overall
and per biological classes in % for the scaled peak areas per metabolite. CMD: calibration mix dilution.
Number of replicates vary due to occasional misinjections. Supplementary Table S6. Incubation
temperature tested for optimization of derivatization conditions. Table of relative standard deviations
(RSD) per compound and the median RSD overall and per biological classes in % for the scaled peak
areas per metabolite. CMD: calibration mix dilution. Number of replicates vary due to occasional
misinjections. Supplementary Table S7. Equilibration time tested for optimization of derivatization
conditions. Table of relative standard deviations (RSD) per compound and the median RSD overall
and per biological classes in % for the scaled peak areas per metabolite. CMD: calibration mix
dilution. Number of replicates vary due to occasional misinjections. Supplementary Table S8.
Individual relative standard deviation (RSD in %) per compound in n = 45 human plasma samples.
AA: amino acids. TCA: Tricarboxylic acid cycle. Supplementary Table S9. Individual relative
standard deviation (RSD in %) per compound in n = 18 mouse liver samples. AA: amino acids. TCA:
Tricarboxylic acid cycle. Supplementary Table S10. Individual relative standard deviation (RSD in
%) per compound in n = 9 pooled quality control samples from three batches. AA: amino acids.
TCA: Tricarboxylic acid cycle. Supplementary Table S11. Ratios between the individual TMS groups
for comparison of on-line, off-line and off-line with on-line conditions (OLOPL). Supplementary
Figure S1. Concentration range of compounds in human plasma. A calibration mixture with
high (1:1), middle (1:10) and low (1:100) concentrations were used (n = 5 replicates for calibration
mixture and n = 45 for plasma). Supplementary Figure S2. Concentration range of compounds
in human serum (pooled quality control samples). A calibration mixture with high (1:1), middle
(1:10) and low (1:100) concentrations were used (n = 5 replicates for calibration mix and n = 9 serum
samples). Supplementary Figure S3. Comparison of initial (starting on-line settings) and optimized
(optimized on-line settings) auto sampler settings. The relative standard deviation of alkane 32
and the number of failed injections decreased from 68% to 8% and 18/59 (31%) to 0/42 (0%) in
human plasma or solvent only, respectively. Supplementary Figure S4. Violin plots showing the
distribution of the normalized peak area (log2 from metabolite normalized area ratio) compared
to the original parameters. Supplementary Figure S5. Total ion chromatogram of a representative
plasma sample analyzed with on-line derivatization. Insets display a composite of the extracted
ion chromatograms for the top 3 masses for the requisite compounds. Compounds which have
persistently poor peak shapes throughout a batch are normally removed by successive quality control
checks before processing to statistical analysis.
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